Centene Corporation (CNC) Shares Fall ~10% Pre-Market After Reporting Q2 2025 Diluted Loss Per Share, Class Action Lawsuit Over “Inflated Guidance” Pending

Core Viewpoint - Centene Corporation experienced a significant decline in stock price following the release of disappointing Q2 2025 financial results, leading to a class action lawsuit from investors alleging misleading statements about the company's financial health and market conditions [1][2][4][5]. Financial Performance - Centene reported a GAAP diluted loss per share of -$0.51 for Q2 2025, primarily due to a reduction in the company's net 2025 Marketplace risk adjustment revenue transfer estimate [4]. - The company withdrew its 2025 financial guidance on July 1, 2025, after a review revealed lower-than-expected market growth and higher morbidity levels than previously assumed, resulting in a stock price drop of over 40% [6]. Legal Issues - A class action lawsuit, Lunstrum v. Centene Corporation, has been filed, representing investors who purchased Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [2][4]. - The lawsuit claims that Centene's leadership misled investors by presenting an overly optimistic view of the company's financial health, despite internal data indicating lower enrollment and higher morbidity rates [5][7]. Market Conditions - Centene's public statements had previously suggested expanding market share and robust business performance, particularly in serving underinsured and uninsured populations, which the lawsuit argues were not aligned with actual operational metrics [5][7]. - A preliminary analysis indicated that more than two-thirds of Centene's Marketplace share showed lower-than-expected enrollment, contradicting the company's optimistic reports [5].